Both involve air movement
doi: 10.1056/NEJMoa2022190 64 AnkerSDButlerJFilippatosGSJamalWSalsaliASchneeJet al
With seven additional Phase 3 readouts expected in 2026, we believe retatrutide could become an important option for patients with significant weight loss needs and certain complications, including knee osteoarthritis." An investigational once-weekly triple hormone receptor agonist, retatrutide is a single molecule that activates the body's receptors for GIP, GLP-1, and glucagon
Based on these results, semaglutide is expected to be submitted to FDA for MASH in 2025, potentially becoming the first GLP-1 RA officially approved for MASH
Making your decision: the practical framework After reviewing all the dosage data, side effects, timelines, and mechanisms, the decision between retatrutide and tirzepatide comes down to a handful of practical questions
Want the gentle lane explained? Read our guide to microdosing semaglutide, or compare starting doses side by side in the GLP-1 microdosing dose chart